Deutsch
English
Русский

Universitätsklinikum Würzburg 

ZIM (Zentrum Innere Medizin)
Haus A3/A4 

Oberdürrbacherstr. 6

97080 Würzburg

ZOM / ZIM

Publikationen 2013

Dawood FZ, Khan F, Roediger MP, Zhang ZM, Swaminathan S, Klinker H, Hoy J, Lundgren JD, Neaton JD, Soliman EZ; INSIGHT SMART Study Group.
Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study).
Am J Cardiol. 2013 Jan 1;111(1):118-24. doi: 10.1016/j.amjcard.2012.08.054.
Impact Factor: 3.425

Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, Puoti M, Romero-Gómez M, Wedemeyer H, Zeuzem S.Clinical management of drug-drug interactions in HCV therapy: challenges and solutions.
J Hepatol. 2013 Apr;58(4):792-800. doi: 10.1016/j.jhep.2012.10.027.
Impact Factor: 10.401

Innes S, Schulte-Kemna E, Cotton MF, Zöllner EW, Haubrich R, Klinker H, Sun X, Jain S, Edson C, van Niekerk M, Innes ER, Rabie H, Browne SH.
Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children.
Pediatr Infect Dis J. 2013 Jun;32(6):e254-62. doi: 10.1097/INF.0b013e3182814b30.
Impact Factor: 3.135

Knop V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Neumann K, Sarrazin C, Zeuzem S, Berg T.
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
Ann Hepatol. 2013 Mar-Apr;12(2):190-8.
Impact Factor: 2.193

Heinz WJ, Einsele H, Helle-Beyersdorf A, Zirkel J, Grau A, Schirmer D, Lenker U, Klinker H.
Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.
Transpl Infect Dis. 2013 Oct;15(5):449-56. doi: 10.1111/tid.12108.
http://www.ncbi.nlm.nih.gov/pubmed/23890126
Impact Factor: 2.250

Mauss S, Klinker H.
Drug-drug interactions in the treatment of HCV among people who inject drugs.
Clin Infect Dis. 2013 Aug; 57 Suppl 2:S125-8. doi: 10.1093/cid/cit299
Impact Factor: 9.416

Gunda DW, Kasang C, Kidenya BR, Kabangila R, Mshana SE, Kidola J, Kalluvya SE, Kongola GW, Klinker H.
Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
PLoS One. 2013 Sep 10;8(9):e75118. doi: 10.1371/journal.pone.0075118
Impact Factor: 3.534

von Bibra M, Rosenkranz B, Pretorius E, Rabie H, Edson C, Lenker U, Cotton M, Klinker H.
Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?
Paediatr Int Child Health. 2013 Sep 2.
Impact Factor: 0.982

Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group.
Platelet count kinetics following interruption of antiretroviral treatment.
AIDS. 2013 Jan 2;27(1):59-68. doi: 10.1097/QAD.0b013e32835a104d
Impact Factor: 6.557

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.
PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249.
Impact Factor: 3.534

Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups.
The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies.
PLoS One. 2013;8(2):e57121. doi: 10.1371/journal.pone.0057121.
Impact Factor: 3.534

Saira K, Lin X, DePasse JV, Halpin R, Twaddle A, Stockwell T, Angus B, Cozzi-Lepri A, Delfino M, Dugan V, Dwyer DE, Freiberg M, Horban A, Losso M, Lynfield R, Wentworth DN, Holmes EC, Davey R, Wentworth DE, Ghedin E; INSIGHT FLU002 Study Group; INSIGHT FLU003 Study Group.
Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus.
J Virol. 2013 Jul;87(14):8064-74. doi: 10.1128/JVI.00240-13.
Impact Factor: 4.648

Springer, J, Morton, CO, Perry, M, Heinz, WJ, Paholcsek, M, Alzheimer, M, Rogers, TR, Barnes, RA, Einsele, H, Loeffler, J, White, PL.
Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients.
J Clin Microbiol 2013; 51(5): 1445-1450.
http://www.ncbi.nlm.nih.gov/pubmed/23426930
Impact Factor: 4.232

Rogers TR, Morton CO, Springe, J, Conneally E, Heinz W, Kenny C, Frost S, Einsele H, Loeffler J.
Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies.
Br J Haematol 2013; 161(4): 517-524.
http://www.ncbi.nlm.nih.gov/pubmed/23614624
Impact Factor: 4.959

Reinwald M, Spiess B, HeinzWJ, Heussel CP, Bertz H, Cornely OA, Hahn J, Lehrnbecher T, Kiehl M, Laws HJ, Wolf HH, Schwerdtfeger R, Schultheis B, Burchardt A, Klein M, Durken M, Claus B, Schlegel F, Hummel M, Hofmann WK,Buchheidt D.
Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive Aspergillosis enhances diagnostic capabilities.
J Clin Microbiol 2013; 51(12): 4178-4185.
http://www.ncbi.nlm.nih.gov/pubmed/24108612

Impact Factor: 4.232

Pagano L, Cornely OA, Busca A, Caira M, Cesaro S, Gasbarrino C, Girmenia C, HeinzWJ, Herbrecht R, Lass-Florl C, Nosari A, Potenza L, Racil Z, Rickerts V, Sheppard DC, Simon A, Ullmann AJ, Valentini CG, Vehreschild JJ, Candoni A, Vehreschild MJ.
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.
Haematologica 2013; 98(10): e127-130.
http://www.ncbi.nlm.nih.gov/pubmed/23716556

Impact Factor: 5.868

Nucci M, Marr KA, Vehreschild MJ, De Souza CA, Velasco E, Cappellano P, Carlesse F, Queiroz-Telles F, Sheppard DC, Kindo A, Cesaro S, Hamerschlak N, Solza C, HeinzWJ, Schaller M, Atalla A, Arikan-Akdagli S, Bertz H, Galvao Castro C Jr., Herbrecht R, Hoenigl M, Harter G, Hermansen NE, Josting A, Pagano L, Salles MJ, Mossad SB, Ogunc D, Pasqualotto AC, Araujo V, Troke PF, Lortholary O, Cornely OA, Anaissie E.
Improvement in the outcome of invasive fusariosis in the last decade.
Clin Microbiol Infect 2013 Oct 1. doi: 10.1111/1469-0691.12409. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/24118322
Impact Factor: 5.197

Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely OA, Loffler J, Ruhnke M.
Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.
Eur J Clin Microbiol Infect Dis 2013; 32(5): 679-689. www.ncbi.nlm.nih.gov/pubmed/23271674
Impact Factor: 2.544

HeinzWJ, Egerer G, Lellek H, Boehme A, Greiner J.
Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.
Mycoses 2013; 56(3): 304-310.
http://www.ncbi.nlm.nih.gov/pubmed/23170837
Impact Factor: 1.805

S. Heimann, O. A. Cornely, L. Meintker, W. Heinz, T. Schroeder, M. J. Vehreschild, H. Wisplinghoff, J. J. Vehreschild Different Doses of Micafungin for Prophylaxis of Invasive Fungal Diseases: A Web-based Non-Interventional Trial in Four Large University Hospitals in Germany;
53st ICAAC, Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver 10-13.9.2013, Abstract M-250

Reinwald M., Spiess B1, Heinz W., Bertz H., Heussel C.P., Vehreschild M.J., Schultheis B., Duerken M., Hofmann W.-K., Buchheidt D . Untersuchung von Biopsaten und Pleuraergüssen mittels Aspergillus-spezifischer PCR in immunsupprimierten Patienten bei Verdacht auf das Vorliegen einer invasiven Aspergillose erweitert die diagnostischen Möglichkeiten / Aspergillus PCR based investigation of biopsies and pleural effusions in immunocompromised patients with suspected invasive aspergillosis enhances diagnostic capabilities;
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Wien 18.-22.10.2013, P-269.

Heinz WJ.
Welche Bedeutungen haben Infektionen durch Schimmelpilze?
In: Wiesmüller GA, Heinzow B, Herr CEW editors. Gesundheitsrisiko Schimmelpilze im Innenraum. 1ed. Heidelberg; Ecomed Medizin; 2013. p. 73-80.

Heinz WJ.
Serumspiegel und Effizienz von Antimykotika.
In: Schmitt M, editor. Antimykotische Prophylaxe bei Neutropenie und Immundefizienz. Bremen: UNI-MED 2013. p. 25-44.

H. Wedemeyer, S. Mauss, H.W. Busch, A. Umgelter, P. Buggisch, H. Klinker, S.
Zeuzem, W. Iraqi, A. Hill, J.M. Läuffer, I. Lonjon-Domanec, M. Colombo
Treatment of Hepatitis C genotype 1 patients with severe fibrosis or compensated
cirrhosis: the German telaprevir early access program 29. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber, 25.-
26.1.2013, Hannover, Abstract P5.72, Z Gastroenterol 2013; 51: 149

J. Fischer, S. Böhm, D. Deichsel, V. Knop, H. Klinker, B. Möller, J. Rasenack, H.
Hinrichsen, U. Spengler, P. Buggisch, C. Sarrazin, T. Berg
Association of genetic variants in innate immunity genes with spontaneous viral clearance
and with interferon response in chronic hepatitis C virus infection 29. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber, 25.-
26.1.2013, Hannover, Abstract P5.17, Z Gastroenterol 2013; 51: 133

J. Fischer, S. Böhm, D. Deichsel, V. Knop, H. Klinker, B. Möller, J. Rasenack, H.
Hinrichsen, U. Spengler, P. Buggisch, C. Sarrazin, T. Berg
Association of a genetic variant of the toll-like receptor 9 (TR9) with spontaneous viral
Clearance and with interferon response in chronic hepatitis C
48th Annual Meeting of the European Association for the Study of the Liver (EASL),
Amsterdam, 24.-28.4.2013, Abstract/Vortrag 9, J Hepatol 2013; 58 (Suppl 1): S4

M. Rau, J. Schmitt, T. Kudlich, K. Spanaus, H. P. Tony, H. Klinker, B. Müllhaupt, A.
Geier
Serum IP-10 levels are associated with higher DPPIV serum activity and increased CD4-
CXCR3positive cells in patients with chronic hepatitis C
48th Annual Meeting of the European Association for the Study of the Liver (EASL),
Amsterdam, 24.-28.4.2013, Poster 488, J Hepatol 2013; 58 (Suppl 1): S200

D. Clemens, U. Lenker, E. Pretorius, J. Taljaard, B. Rosenkranz, M. Cotton, H. Klinker
Efavirenz- und Nevirapin Plasmakonzentrationen im Rahmen der antiretroviralen Therapie bei
HIV-infizierten schwangeren Frauen in Südafrika
6. Deutsch-Österreichischer AIDS-Kongress, Innsbruck 12.-15.6.2013, Poster Nr. 078,
Vortrag 13.6.13
 
H. Klinker
Entscheidend ist, was ankommt – besondere Herausforderungen bei Suchtpatienten unter
HCV-Tripletherapie
14. Interdisziplinärer Kongress für Suchtmedizin, München, 04.-06-07.2013 Abstract, Suchtmedizin in Forschung und Praxis 2013; 15: 134

Fischer J., Böhm S., Deichsel D., Knop V., Klinker H., Möller B., Rasenack J., HinrichsenH., Spengler U., Buggisch P., Sarrazin C., Berg T.
Einfluss von Polymorphismen im Toll-like Rezeptor 9 (TLR9) Gen auf den natürlichenVerlauf einer Hepatitis C Virusinfektion.
68. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechsel-krankheiten, 11.-14.09.2013, Nürnberg, K98, Z Gastroenterol 2013; 51: 902

D. Tappe, T. Holzmann, S. Poppert, A. Haeupler, B. Muntau, P. Racz, J. Bergholz, U. Mahlke, H. Lobeck, H. Klinker, K. Heldwein, C. Roesel, D. Theegarten Invasive human infections with the emerging larval tapeworm pathogen Taeniacrassiceps
Annual Meeting of the German Society for Infectious diseases (DGI), Rostock 22.-25.9.2013, Poster